The investigators found that a factor called Axin2 is essential for normal repair of nerves stripped of myelin. This is the process called remyelination.
A small molecule XAV939, which stabilises levels of Axin2, accelerates remyelination.
These findings indicate that Axin2 is an essential regulator of remyelination and that it might serve as a pharmacological target for drug development for MS'ers.
"Another promising target for the Pharma industry to develop drugs to promote remyelination and recovery in MS'ers. The NMSS Promise 2010 delivers another target! Are you happy?"
[Epub ahead of print] Fancy et al. Axin2 as regulatory and therapeutic target in newborn brain injury and remyelination. Nat Neurosci. 2011 Jun 26. doi: 10.1038/nn.2855.
"Well done Steve and colleagues."
Further reading: myelin